ライフサイエンスコーパス: phase @1 trial

1 of several studies (including two randomized phase III trials).

2 with acceptable safety and tolerability in a phase 1 trial.

3 al blood of patients receiving NKTR-214 in a phase 1 trial.

4 efit, which requires further assessment in a phase 2 trial.

5 with PCa were prospectively enrolled in this phase 2 trial.

6 bstudy of a double-blind, placebo-controlled phase 2 trial.

7 ptoms with an acceptable safety profile in a phase 2 trial.

8 andomized, double-blind, placebo-controlled, phase 2 trial.

9 double-blind, randomised, placebo-controlled phase 3 trial.

10 bicin as second-line therapy in a randomised phase 3 trial.

11 ompared with standard-of-care sorafenib in a phase 3 trial.

12 icentre, open-label, randomised, controlled, phase 3 trial.

13 s was a randomized, controlled, double-blind phase 3 trial.

14 sociated variants (RAVs) among subjects in a Phase 3 trial.

15 entre, double-blind, randomised, controlled, phase 3 trial.

16 Randomized, controlled, double-blind, phase 3 trial.

17 further investigation in a large multicenter phase 3 trial.

18 m patients who participated in the Short-HER phase 3 trial.

19 e systemic dose range considered safe in the Phase I trial.

20 e-blind, placebo-controlled, dose-escalation Phase I trial.

21 showed clinical activity and tolerability in phase 1 trials.

22 ng results in patients with high-risk AML in phase 2 trials.

23 th moderate-to-severe atopic dermatitis in a phase 2b trial.

24 eld with an emphasis on drugs in Phase 2 and Phase 3 trials.

25 ed liposomal ciprofloxacin (ARD-3150) in two phase 3 trials.

26 cal trials, and 1.00 (95% CI = 0.95-1.06) in phase 3 trials.

27 ulvestrant warrants further investigation in phase 3 trials.

28 recurring pancreatic cancer in a prospective phase II trial.

29 ients enrolled in our investigator-initiated phase II trial.

30 90)Y-DOTATOC in the setting of a prospective phase II trial.

31 ebo in a double-blinded, placebo-controlled, phase IIb trial.

32 bo, in a double-blinded, placebo-controlled, phase IIb trial.

33 lase for Intracerebral Hemorrhage Evacuation Phase III trial.

34 This was a randomized, open-label, phase III trial.

35 ntrolled series, although was not in a small phase III trial.

36 t with the results coming from past clinical phase IIa trials.

37 overall survival (OS) benefit in randomized phase III trials.

38 ble formulation for HIV PrEP being tested in Phase III trials.

39 new agents are currently being evaluated in phase III trials.

40 vaccine candidates, and many have moved into phase III trials.

41 ce this combinatorial treatment toward early-phase human trials.

42 hibitors are currently being tested in early phase clinical trials.

43 ing therapeutic candidate currently in early-phase clinical trials.

44 dings into improved patient outcomes in late-phase clinical trials.

45 previously reported primary analysis of this phase 3 trial, 12 months of adjuvant dabrafenib plus tra

46 In separate Phase 2 trials, 120 patients received maribavir for cyto

47 In this double-blind, placebo-controlled, phase 2 trial, 140 patients with noncirrhotic NASH, diag

48 irst stage of this adaptive, non-comparative phase 2 trial, 67 patients with metastatic TNBC were ran

49 In a phase 2 trial, a twice-yearly injection of inclisiran, a

50 In this phase 2 trial, AA supplementation protected against a de

51 ive probability of success in a hypothetical phase III trial, adjusting for biomarker covariates.

52 In this prospective multicentre phase 2 trial, adult patients aged 18-75 years who recei

53 This successful phase I trial also provides a possible avenue for achiev

54 asone (KRd), has shown promising efficacy in phase 2 trials and might improve outcomes compared with

55 s Perspectives, we highlight key elements of phase I trials and discuss how each one of them contribu

56 of efficacy between proof-of-concept (i.e., Phase II trials) and pivotal, confirmatory (Phase III tr

57 Evobrutinib reduced MRI activity in a phase 2 trial, and a phase 3 trial is underway, in patie

58 cell trophic factor BAFF, was ineffective in phase III trials, and efgartigimod, which depletes antib

59 Phase 3 trials are needed to assess clinical efficacy.

60 Phase 3 trials are needed to conclusively show an overal

61 Data from phase I and phase II trials are already available for several vaccin

62 A phase 1 trial assessed the safety of intravitreal OPT-30

63 e findings must be investigated further in a phase 3 trial assessing treatment outcomes.

64 Phase II trials assessing repurposed agents must conside

65 o-controlled, parallel-group, registrational phase 2 trial at 11 institutions in the United States, E

66 double-blind, randomised, placebo-controlled phase 2 trial at 70 centres in Australia, Belgium, Canad

67 We did a multicentre, single-arm, phase 2 trial at eight cancer centres in the USA.

68 ntre, open-label, non-randomised, single-arm phase 2 trial at seven sites in the USA.

69 did an open-label, multicentre, randomised, phase 2 trial at six hospitals in China.

70 We did a single-centre, single-arm, phase 2 trial at the Memorial Sloan Kettering Cancer Cen

71 s randomised, active-controlled, open-label, phase 3 trial at 16 clinical sites, we enrolled children

72 label, sponsor-blind, randomised, controlled phase 3 trial at 209 cancer treatment centres in 23 coun

73 We did an open-label randomised controlled phase 3 trial at 32 head and neck treatment centres in I

74 We did this randomised, double-blind, phase 3 trial at 41 US medical centres to assess the eff

75 In early-phase clinical trials, chemotherapeutic agents targeting

76 This double-blind, placebo-controlled phase 2b trial compared progression of coronary artery c

77 Our phase III trial compared neoadjuvant versus concurrent i

78 SWOG-1211 is a randomised phase 2 trial comparing eight cycles of lenalidomide (25

79 data from 3 Indonesian randomized controlled phase 2 trials comparing oral rifampicin 450 mg (~10 mg/

80 Here, we report results of IMmotion151, a phase 3 trial comparing atezolizumab plus bevacizumab ve

81 andomised, double-blind, placebo-controlled, phase 3 trial comparing dabrafenib 150 mg orally twice d

82 ucted a multicenter, randomized, open-label, phase 3 trial comparing the efficacy and safety of oral

83 INFORM is a randomized, multicenter, phase II trial comparing pathologic complete response (p

84 ntrolled, observer-blinded, dose-escalation, phase 1 trial conducted in the United States, we randoml

85 novel drug targets, interpretation of early-phase clinical trial data, and development of predictive

86 A previous phase 2 trial demonstrated improved resolution of organ

87 This review summarizes important phase 3 trial design considerations for industry and pro

88 A Simon two-stage phase II trial design was used to distinguish between Re

89 s was an open-label, multicentre, single-arm phase 2 trial done at 18 hospitals in Spain.

90 This study was an open-label, single-arm, phase 2 trial done at 38 clinics or hospitals in France,

91 This was a single-arm, phase 2 trial done at the MD Anderson Cancer Center (Hou

92 was an open-label, single-arm, three-cohort phase 2 trial done at the National Cancer Institute (Bet

93 double-blind, randomised, placebo-controlled phase 2a trial done at eight sites in Brazil, Malawi, So

94 s an international, multicentre, randomised, phase 3 trial done across 117 hospitals in the UK, Austr

95 en-label, active-controlled, parallel-group, phase 3 trial done at 111 academic and community practic

96 andomised, double-blind, placebo-controlled, phase 3 trial done at 147 hospitals in 36 countries.

97 ouble-blind, randomised, placebo-controlled, phase 3 trial done at 182 study locations including acad

98 14 is a multicentre, randomised, open-label, phase 3 trial done at 196 sites in 21 countries.

99 andomised, double-blind, placebo-controlled, phase 3 trial done at 92 hospitals, clinics, and medical

100 KEYNOTE-185 was a randomised, open-label, phase 3 trial done at 95 medical centres across 15 count

101 s was a randomised, open-label, multicentre, phase 3 trial done at ten centres in Canada and one in A

102 our knowledge, REACH-2 is the first positive phase 3 trial done in a biomarker-selected patient popul

103 andomised, double-blind, placebo-controlled, phase 3b trial done at 64 sites (hospitals, clinics, or

104 HD was an open-label, randomised, controlled phase 4 trial done at Massachusetts General Hospital.

105 el, multicentre, parallel-group, randomised, phase 3 trial (done in 130 UK hospitals) in which postme

106 2503) is an ongoing multicentre, two-cohort, phase 3 trial, done at 108 centres in 22 countries.

107 andomised, placebo-controlled, double-blind, phase 3 trial, done in 209 sites in 29 countries, we ran

108 andomised, placebo-controlled, double-blind, phase 3 trial, done in 246 academic centres and communit

109 vir (DRV+r) and efavirenz (EFV) in 2 ongoing phase 3 trials: DRIVE-FORWARD (NCT02275780) and DRIVE-AH

110 In the absence of randomised phase 3 trials, early clinical studies show improved sur

111 ind, randomized, placebo-controlled, 6-month phase 3 trials (Elaris Uterine Fibroids 1 and 2 [UF-1 an

112 This open-label, global phase II trial enrolled 129 patients (median age, 65 yea

113 This phase III trial enrolled adult patients with brain metas

114 We conducted a randomized, open-label, phase 3 trial evaluating the PARP inhibitor olaparib in

115 tional, multicentre, randomised, controlled, phase 3 trial evaluating tumour bed boost and hypofracti

116 SIMPLIFY and D3FEAT are phase 4 trials evaluating the efficacy of DAA among peop

117 c approach has been validated in randomised, phase 3 trials, evaluation of response to neoadjuvant ch

118 en-label, investigator-initiated, randomised phase 2 trial following a selection (or pick-the-winner)

119 esmetirom (MGL-3196), which are currently in phase 3 trials for the treatment of NASH, are reviewed.

120 , was found to be safe, yet ineffective in a phase II trial for type 2 diabetes.

121 nstrate their efficacy and safety in pivotal phase III trials for registration.

122 Here, in the phase I trial GAPVAC-101 of the Glioma Actively Personal

123 es for glioblastoma multiforme (GBM) in late-phase clinical trials has directed interest toward adopt

124 linical models of neonatal brain injury, and phase 2 trials have suggested possible efficacy; however

125 Phase 3 trials have also been completed for bempedoic ac

126 olled in two independent European randomized phase III trials (IFM/DFCI2009 and EMN02/HO95).

127 y and preliminary activity results from this phase 1 trial in all patients with HER2-positive advance

128 andomised, double-blind, placebo-controlled, phase 2 trial in 20 German academic medical centres.

129 We performed a double-blind, phase 2 trial in adults with moderate to severe CD and i

130 , non-randomised, single-arm, single centre, phase 2 trial in patients aged 18 years or older with HE

131 We did a multicentre, single-arm, two-stage, phase 2 trial in patients with advanced Ewing sarcoma or

132 ouble-blind, randomised, placebo-controlled, phase 2 trial in patients with decompensated cirrhosis a

133 randomized, double-blind, placebo-controlled phase 3 trial in 1154 preterm infants of 1 or 2 doses of

134 In this ongoing phase 3 trial in 23 countries, we enrolled patients with

135 an open-label, randomised, non-inferiority, phase 3 trial in 31 transplantation centres in France, G

136 EXPLORER-HCM is a phase 3 trial in oHCM testing a first-in-class, targeted

137 BE is an open-label, randomised, controlled, phase 3 trial in patients with untreated, unresectable,

138 mTOR, are currently being evaluated in early phase clinical trials in children with high-risk MYCN-dr

139 ProCAID was a placebo controlled randomized phase II trial in mCRPC.

140 dy was a multicenter, open-label, multi-arm, phase II trial in patients with PI3K pathway-activated g

141 This is a French multicenter randomized phase II trial in patients with resectable high-risk T3,

142 o-to-one randomized, controlled, open-label, phase II trial in patients with untreated RAS wild-type

143 se-developed biologics, have been studied in phase II trials in patients with EoE; and (3) novel diet

144 In this randomized phase III trial in 16 centers, patients with resectable

145 In PARADIGMS, a double-blind phase III trial in 215 paediatric patients with multiple

146 dary outcomes in clinical trials, an ongoing phase III trial in patients with diabetic kidney disease

147 E1609 was a phase III trial in patients with resected cutaneous mela

148 odium falciparum malaria infection completed phase III trials in 2014 and demonstrated efficacy again

149 Two phase III trials in adult patients with non-small-cell l

150 The multicenter randomized phase III trial included patients with cutaneous melanom

151 andomised, double-blind, placebo-controlled, phase 2b trial involved 25 hospitals in the USA.

152 In this ongoing phase 2 trial involving outpatients with recently diagno

153 cytokine trap, were studied previously in a phase 2 trial involving patients with recurrent pericard

154 In the 5-year follow-up of a phase 3 trial involving patients who had resected stage

155 ed an open-label, international, randomized, phase 3 trial involving patients younger than 18 years o

156 in cancer, including data from several late-phase clinical trials involving FRalpha-targeted therapi

157 activity with low toxicity in a prospective phase II trial involving 30 men with metastatic castrati

158 ducted a post hoc analysis of the vandetanib phase III trial involving patients with advanced medulla

159 randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010/HPX1002) at Beth Israel Deacone

160 duced MRI activity in a phase 2 trial, and a phase 3 trial is underway, in patients with relapsing mu

161 Further investigation in a pivotal phase 3 trial is underway.

162 n this multicentre, double-blind, randomised phase 3 trial (JADE MONO-1), patients (aged >=12 years)

163 In a phase 3 trial, letermovir reduced clinically significant

164 tamol PET and corresponding MR images from a phase II trial (<em>n</em> = 70), including subjects ran

165 In this double-blind, phase 3 trial, men with nonmetastatic, castration-resist

166 A phase 3 trial (MERCURY-1) investigated efficacy and safe

167 In this phase 2 trial, most children with neurofibromatosis type

168 specified open-label extension analysis of a phase 1 trial (NCT00412321) and a phase 2 trial (NCT0102

169 escribed here is a participant in an ongoing phase I trial (NCT00902044; active, not recruiting), and

170 lysis of a phase 1 trial (NCT00412321) and a phase 2 trial (NCT01024036), done at 26 hospitals worldw

171 The SAKK trial 75/08 was a multicenter phase III trial (NCT01107639) comparing induction chemot

172 therapy, are being compared in a randomised phase 2 trial (NCT01896999).

173 Here we performed a randomized phase 2 trial ( NCT02130466 ), in which patients with tr

174 We conducted an early-phase clinical trial (NCT02415881) and previously report

175 server-blind, randomized, placebo-controlled phase I trial (NCT03300050), safety and immunogenicity o

176 afety and immunogenicity data from this U.S. phase 1 trial of two vaccine candidates in younger and o

177 This phase 1 trial of TY014 did not identify worrisome safety

178 In this small phase 1b trial of limited duration, the safety and toler

179 In a phase 1b trial of patients with UC, we evaluated the saf

180 We performed a double-blind phase 2 trial of 104 patients with NAFLD in the United K

181 We did a multicentre, phase 2 trial of axitinib given on an individualised dos

182 This prospective phase 2 trial of daratumumab monotherapy for the treatme

183 y videos were prospectively collected from a phase 2 trial of mirikizumab with 249 patients from 14 c

184 nducted a 12-week, randomized, double-blind, phase 2 trial of nemolizumab (at a dose of 0.5 mg per ki

185 We did a single-arm, phase 2 trial of patients recruited from the Dana-Farber

186 In a phase 2 trial of patients with active EoE, dupilumab red

187 In a phase 2 trial of patients with CD, upadacitinib induced

188 In a phase 2 trial of patients with EoE, we found RPC4046 (a

189 In a phase 2 trial of patients with NASH, aldafermin reduced

190 In a phase 2 trial of patients with primary progressive multi

191 We did a phase 2 trial of pembrolizumab in patients with non-smal

192 We conducted an open-label, phase 2 trial of selumetinib to determine the objective

193 mmunoglobulin A [IgA]) immune responses in a phase 2 trial of Takeda's bivalent norovirus virus-like

194 andomized, double-blind, placebo-controlled, phase 3 trial of early vitamin D(3) supplementation in c

195 ion in confirmed disability progression in a phase 3 trial of patients with relapsing multiple sclero

196 Two phase 3 trials of inclisiran in patients with elevated L

197 We searched all phase 3 trials of medical treatments for acute ischemic

198 educed relapse rates and MRI activity in two phase 3 trials of patients with relapsing multiple scler

199 localized-stage FL, uniformly treated within phase 3 trials of the German Low-Grade Lymphoma Study Gr

200 Indeed, early-phase clinical trials of T(reg) cell therapy have shown

201 We performed two phase I trials of the histone deacetylase inhibitor vori

202 CITN-10 is a single-arm, multicenter phase II trial of 24 patients with advanced MF or SS.

203 To this end, we conducted a phase II trial of enzalutamide treatment (160 mg/d) in 3

204 A phase II trial of iadademstat in combination with azacit

205 dose escalation by post hoc analysis of the phase III trial of rupatadine for Japanese patients with

206 igh SVR12 rates, equivalent to those seen in Phase III trials of other pangenotypic options, and has

207 However, Phase III trials of this combination in other genotypes

208 a measure of deviation between instantaneous phases of trials) of low frequency local field potential

209 nt advances in preclinical studies and early phase clinical trials offer renewed promise for immunolo

210 In this interim analysis of a phase 2 trial, one of three doses of neutralizing antibo

211 andomised, placebo-controlled, double-blind, phase 1 trial, participants were enrolled at the Nationa

212 In this open-label, single-arm, phase 3 trial, participants were recruited from 24 acade

213 In this small phase 2 trial, patients with PDGFRA-negative hypereosino

214 In this open-label, single-arm, phase 2 trial, patients with recurrent or advanced, inop

215 nt complete) randomised, placebo-controlled, phase 3 trial, patients aged 18 years or older who had p

216 this randomised, double-blind, multicentre, phase 3 trial, patients aged 18 years or older with rela

217 against the allogeneic donor.METHODSIn this phase I trial, patients received either 1.5 x 106 MICs p

218 In this open-label phase II trial, patients with resected stage IA to IIIA

219 In this randomized phase III trial, patients who had local treatment of one

220 In a prospective, multicenter, randomized phase III trial, patients with cN0 early breast cancer o

221 In this international phase III trial, patients with stage IIIB or IV adenocar

222 omalizumab safety and efficacy in CRSwNP in phase 3 trials (POLYP 1 and POLYP 2).

223 andomised, double-blind, placebo-controlled, phase 2 trial, postmenopausal women aged at least 18 yea

224 Our two phase I trials provide preliminary evidence supporting t

225 ies for this group of disorders are in early-phase clinical trial, realistic expectations are that su

226 Early-phase clinical trial results have demonstrated the remar

227 In a phase 2 trial, ruxolitinib, a selective Janus kinase (JA

228 The primary endpoint of phase 3 trials should be functional cure; HBsAg loss in

229 iosimilar candidates, which are currently in phase 3 trials, showing promising early results.

230 randomized, placebo-controlled, double-blind phase II trial (SORMAIN; German Clinical Trials Register

231 , and has moved at an unprecedented speed: a phase I trial started in March 2020 and there are curren

232 A multi-cohort, phase 2 trial (TELLOMAK) is underway to confirm the acti

233 MC1273 was a single-arm phase II trial testing an aggressive course of RT de-esc

234 Phase II trials) and pivotal, confirmatory (Phase III trials) testing.

235 allel-group, placebo-controlled, multicentre phase 2 trial that evaluated the safety and efficacy of

236 We report the results of IMvigor130, a phase 3 trial that compared atezolizumab with or without

237 , randomised, open-label, active-controlled, phase 3 trial that enrolled patients between Feb 9, 2015

238 ouble-blind, randomised, placebo-controlled, phase 3 trial that was done at 204 centres in 25 countri

239 T01513239, respectively), global, randomized phase 3 trials that assessed the efficacy and safety of

240 CALGB/SWOG 80405 was a randomized phase III trial that found no statistically significant

241 In the planned primary analysis of a phase 3 trial, the median metastasis-free survival was s

242 pite promising preclinical results and early-phase clinical trials, the goal of developing safe, effe

243 Two phase III trials-the Trial Assigning Individualized Opti

244 of efficacy awaits an appropriately powered phase 3 trial, this randomized, controlled, multicenter

245 Network multicenter, open-label, randomized phase 2 trial to estimate the difference in day 28 compl

246 We performed a phase 2 trial to evaluate the efficacy and safety of RPC

247 eek, randomized, double-blind, double-dummy, phase 2 trial to investigate the efficacy and safety of

248 We did a phase 2a trial to assess safety after administration of

249 andomized, double-blind, placebo-controlled, phase 2b trial to evaluate the ability of Lactobacillus

250 DISCOVER-2 was a phase 3 trial to assess guselkumab in biologic-naive pat

251 open-label, randomized, multicenter, two-arm phase II trial to investigate cisplatin and gemcitabine

252 mRNA-1273 is currently in a phase III trial to evaluate its efficacy.

253 820 men with mCRPC randomly assigned in nine phase III trials to DP or a DP-containing regimen were c

254 sprYcel (DESTINY) study is a non-randomised, phase 2 trial undertaken at 20 UK hospitals.

255 In a phase 3 trial, up to 48 weeks of treatment with BOT (0.5

256 Here, we report a phase I trial using the Vaxxas HD-MAP to deliver a monov

257 here have guided the design of confirmatory Phase IV trials using ATIV to provide tools to identify

258 A 2-part, phase 1 trial was conducted in healthy adults.

259 Patient enrolment into the phase 1 trial was from June 20, 2005, to Sept 15, 2009,

260 This open-label, consecutive-panel, phase 1b trial was done at Charite Research Organisation

261 This single centre, phase 2 trial was done at the University of Texas MD And

262 This open-label, multicentre, single-arm, phase 2 trial was done at three hospitals in the USA.

263 This single-arm, multicentre, phase 2 trial was done in 19 European academic centres i

264 05, to Sept 15, 2009, and enrolment into the phase 2 trial was from Feb 9, 2010, to Feb 3, 2012.

265 This phase 3 trial was designed to further assess these preli

266 ouble-blind, placebo-controlled, randomised, phase 3 trial was done at 16 university-affiliated centr

267 andomised, double-blind, placebo-controlled, phase 3 trial was done at 36 treatment centres in the US

268 ouble-blind, randomised, placebo-controlled, phase 3 trial was done at 86 sites in 13 countries acros

269 entre, double-blind, randomised, controlled, phase 3 trial was done in 130 academic centres, communit

270 This randomised, double-blind, paired, phase 3 trial was done in 19 European transplant centres

271 ects who received LET as prophylaxis in this Phase 3 trial was low.

272 ospective, pooled analysis of six randomised phase 3 trials was done to investigate disease-free surv

273 lticenter, double-blind, placebo-controlled, phase III trial was conducted across 39 centers in 13 co

274 ELIANA, a global, single-arm, open-label, phase 2 trial, was done in 25 hospitals across Australia

275 This randomised, open-label, non-inferiority phase 3 trial, was done at two research sites in Johanne

276 This multicentre, open-label, randomised, phase 3 trial, was done in 159 academic centres in Germa

277 In this double-blind, single-centre phase 1 trial, we isolated participants in a purpose-bui

278 In this phase 1b trial, we concluded that the i.v. administratio

279 andomized, double-blind, placebo-controlled, phase 2 trial, we administered a series of three monthly

280 ncology multicentre, randomised, open-label, phase 2 trial, we enrolled eligible adults (aged >=18 ye

281 In this double-blind, phase 2 trial, we enrolled patients with major depressio

282 In this double-blind, placebo-controlled, phase 2 trial, we enrolled patients with or without hete

283 In a multicenter, phase 2 trial, we evaluated KTE-X19 in patients with rel

284 In this phase 2 trial, we randomly assigned adults who had sympt

285 In this randomized, double-blind, phase 3 trial, we assigned, in a 2:1 ratio, adults with

286 In this double-blind, placebo-controlled, phase 3 trial, we randomly assigned in a 2:1 ratio 65 pa

287 In an open-label, phase 3 trial, we randomly assigned patients in a 2:1 ra

288 In this double-blind, placebo-controlled, phase 3 trial, we randomly assigned patients undergoing

289 In this phase 3 trial, we randomly assigned patients with advanc

290 In a double-blind, placebo-controlled, phase 3 trial, we randomly assigned patients with very-l

291 s), open-label, non-inferiority, randomised, phase 3 trial, we recruited adult patients (age >=18 yea

292 In this single-arm, open-label, phase 3 trial, we recruited patients from 38 sites acros

293 ospective, pooled analysis of six randomised phase 3 trials, we included patients with stage III colo

294 In two double-blind, double-dummy, phase 3 trials, we randomly assigned patients with relap

295 In this multicenter phase II trial, we evaluated atezolizumab combined with

296 Two randomized phase III trials were identified, and individual patient

297 Industry-sponsored trials (69.6% of phase 3 trials) were significantly more likely to be ran

298 a novel treatment can be obtained in current phase I trials, which can therefore be considered to hav

299 We identified 50 phase 3 trials with 46,008 subjects, 75 early clinical t

300 A randomized, phase II trial with a 2 x 2 factorial design was conduct